Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.33 |
| ▸ | CHRNG | P07510 | 4/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.33 |
| ▸ | CHRND | Q07001 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484839 | 0.83 | MEN1 (0.34) | — | |
| SCHEMBL4473362 | 0.81 | — | — | |
| SCHEMBL4468208 | 0.80 | HSP90AA1 (0.35) | — | |
| SCHEMBL4472455 | 0.79 | SPR (0.34) | CYP11B2 | |
| SCHEMBL4464111 | 0.79 | SSTR5 (0.35) | — | |
| SCHEMBL4473864 | 0.79 | HSD17B10 (0.38) | CYP3A4 | |
| SCHEMBL4463874 | 0.78 | KMT2A (0.42) | CYP3A4 | |
| SCHEMBL4481197 | 0.76 | GRM5 (0.35) | — | |
| SCHEMBL4472622 | 0.76 | SSTR5 (0.39) | — | |
| SCHEMBL4466143 | 0.76 | OPRM1 (0.41) | CHRNB2CHRNA4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | CYP11B2 65/4885CHRNB2 4771/4885CHRNA4 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.